Adverse effect of immunoglobulin, initial encounter

This code signifies an undesirable or harmful reaction experienced by a patient due to the therapeutic administration of an immunoglobulin product. These reactions are not due to an overdose or poisoning, but rather an expected, albeit adverse, physiological response to the medication. It covers the initial phase of treatment for such an adverse event.

This code is appropriate when a patient presents with symptoms like rash, fever, chills, headache, or anaphylaxis following the administration of intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), or other immunoglobulin preparations. It should be used for the first encounter where the adverse effect is being evaluated and treated.

• Always sequence this code first if it is the primary reason for the encounter.
• Utilize an additional code to specify the exact nature of the adverse effect (e.g., rash, anaphylaxis).
• Ensure documentation clearly links the adverse reaction to the immunoglobulin administration and specifies it as an initial encounter.